Atkins G J, Qiao M, Coombe D R, Gowans E J, Ashman L K
Division of Haematology, University of Adelaide, Australia.
Immunol Cell Biol. 1997 Jun;75(3):259-66. doi: 10.1038/icb.1997.40.
A quantitative assay of hepatitis B virus (HBV) binding to hepatocyte plasma membranes was adapted to show that leucocyte plasma membranes bind serum-derived HBV saturably, and that this binding is inhibited using synthetic peptides representative of the large envelope protein of HBV. Using a panel of ligand-blocking monoclonal antibodies (mAb) to opsonin receptors, it was shown that the three classes of Fc gamma R and CR3 are not major receptors for HBV on leucocytes or hepatocytes. It was also shown that HBV does not utilize the receptor for IgA, Fc alpha R, for attachment to leucocytes, despite reported sequence homology between the large envelope protein of HBV and the Fc portion of human IgA. Evidence is presented that the receptor for HBV on leucocytes may differ from the hepatocyte receptor(s), based on synthetic peptide inhibition assays of HBV binding. Furthermore, it was observed that glycosaminoglycans influence the HBV-liver and leucocyte interactions, providing evidence that HBV attachment may be a multi-stage process.
一种用于定量检测乙肝病毒(HBV)与肝细胞质膜结合的方法经调整后显示,白细胞质膜可饱和性地结合血清来源的HBV,并且使用代表HBV大包膜蛋白的合成肽可抑制这种结合。利用一组针对调理素受体的配体阻断单克隆抗体(mAb),研究表明,三类FcγR和CR3并非HBV在白细胞或肝细胞膜上的主要受体。研究还表明,尽管报道称HBV大包膜蛋白与人IgA的Fc部分存在序列同源性,但HBV并不利用IgA受体FcαR来附着于白细胞。基于HBV结合的合成肽抑制试验,有证据表明白细胞上的HBV受体可能与肝细胞膜受体不同。此外,观察到糖胺聚糖会影响HBV与肝脏及白细胞的相互作用,这表明HBV的附着可能是一个多阶段过程。